CHINA RISUN GP (01907) rose more than 5%, reaching a gain of 4.23% at the time of writing to trade at HK$3.19, with a turnover of HK$83.65 million. The increase comes amid heightened geopolitical tensions in the Middle East, which have disrupted global crude oil trade and intensified energy price volatility, subsequently driving up chemical product prices. However, the market has largely viewed this as a temporary disruption, resulting in a noticeable lag in the overall performance of the chemical sector.
Against this backdrop, China's coal chemical industry is increasingly demonstrating its strategic value and investment appeal, owing to its dual advantages in cost and policy support. Analysis from HSBC suggests that if the Middle East conflict persists, leading to a significant rise in oil prices and assuming low risks of demand destruction, the coal chemical sector—with its integrated domestic production chains—stands to benefit clearly.
Previously, Guozheng International highlighted that CHINA RISUN GP is deepening its focus on new materials and fine chemicals. The company's 5,000-ton annual capacity amino alcohol project commenced production in July 2025, and its independently developed adiponitrile process is set to begin operations in April 2026, bypassing traditional bottlenecks in the adiponitrile supply chain. Future expansions in caprolactam capacity are also planned.
Since March 2026, prices of crude oil-related chemical products—including methanol, pure benzene, synthetic ammonia, and caprolactam—have risen substantially due to the international situation. This trend is expected to significantly enhance the performance of the company's chemical business segment this year.
Comments